Tyrosine Kinase Inhibitors

Kinase Inhibitors: Managing Side Effects in GI Cancers

Kinase Inhibitors: Managing Side Effects in GI Cancers

By

A review of adverse effects and recommended management for 3 kinase inhibitors indicated for the treatment of gastrointestinal cancers.

TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI

TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI

By

Patients with chronic lymphocytic leukemia (CLL) who discontinue TKI therapy due to toxicity can successfully be treated with an alternate TKI.

Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC

Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC

By

The addition of vandetanib to a platinum agent and etoposide did not improve time to progression or overall survival in patients with newly diagnosed extensive-stage SCLC.

Cabozantinib May Be More Effective in Patients With Certain Mutations

By

Patients with medullary thyroid cancer who harbor RET M918T or RAS mutations may derive greater clinical benefit from cabozantinib compared with patients who do not have those genetic mutations.

In NSCLC, Erlotinib Appears Effective at Doses Lower Than MTD

In NSCLC, Erlotinib Appears Effective at Doses Lower Than MTD

By

Patients with metastatic non-small cell lung cancer demonstrated prolonged median progression-free survival with the administration of erlotinib below the maximum tolerated dose.

Biomarkers Predict Response to TKI Therapy for Metastatic Renal Cell Carcinoma

Biomarkers Predict Response to TKI Therapy for Metastatic Renal Cell Carcinoma

By

Presence of certain microRNAs (miRNAs) is predictive of response to TKIs and prognosis for patients with metastatic renal cell carcinoma (mRCC).

Social Support Crucial for Patients With CML Receiving Lifelong Targeted Therapy

Social Support Crucial for Patients With CML Receiving Lifelong Targeted Therapy

By

For patients with chronic myeloid leukemia treated with lifelong targeted therapies, social support is crucial for maintaining psychological well-being.

Hyper-CVAD + Ponatinib May Be Superior to Hyper-CVAD + Dasatinib in Ph+ ALL

By

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.

Data Confirm Benefit of Cobimetinib and Vemurafenib in Melanoma

By

Cobimetinib in combination with vemurafenib as a standard first-line approach improves survival in patients with BRAF V600 mutation-positive melanoma, updated results of the coBRIM study.

Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic Phase

Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic Phase

By

A high percentage of patients with CML treated with TKIs achieve deep molecular responses and can safely stop therapy. Initials results of the EURO-SKI trial define prognostic markers that indicate durability of deep molecular responses after stopping TKI therapy.

SRC Kinase Inhibitor Could Be a New Treatment for Breast Cancer

SRC Kinase Inhibitor Could Be a New Treatment for Breast Cancer

By

Scientists discovered the compound eCF506. This compound was more effective than existing medicines at targeting breast cancer cells because it more selectively inhibited SRC tyrosine kinase.

Treatment Compliance and Severe Adverse Events Limit the Use of Tyrosine Kinase Inhibitors in Refractory Thyroid Cancer

Treatment Compliance and Severe Adverse Events Limit the Use of Tyrosine Kinase Inhibitors in Refractory Thyroid Cancer

[OncoTargets and Therapy] This research examines patient compliance with tyrosine kinase inhibitor (TKI) treatment for refractory and progressive thyroid cancer, as well as exploring the efficacy and serious adverse events associated with this treatment.

Increased risk of Severe Infections in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-Analysis

Increased risk of Severe Infections in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-Analysis

[OncoTargets and Therapy] This research examines the risks and benefits associated with using small-molecule vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs).

Afatinib active in many TKI-pretreated patients with NSCLC and uncommon EGFR mutations

Afatinib active in many TKI-pretreated patients with NSCLC and uncommon EGFR mutations

Afatinib is clinically active and well tolerated in many tyrosine kinase inhibitor (TKI)-pretreated patients with non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations, according to a new study.

New tool uses drug spillover to match cancer patients with treatments

New tool uses drug spillover to match cancer patients with treatments

By

A new tool predicts what genetics are truly driving the cancer in any population of cells and helps the user choose the best kinase inhibitor to address the issue.

Profile of neratinib and its potential in the treatment of breast cancer

Profile of neratinib and its potential in the treatment of breast cancer

[Breast Cancer: Targets and Therapy] This research reviews the preclinical as well as clinical data on neratinib.

Use of Pharmacokinetics to Measure Response in CML

Use of Pharmacokinetics to Measure Response in CML

By

What data are available concerning inter- and intrapatient variability in the pharmacokinetics of TKIs in chronic myeloid leukemia?

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side effects in patients

By

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

IMPRESS trial fails to find benefit from more tyrosine kinase inhibitor (TKI) treatment after resistance develops

By

Patients with lung cancer that have developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival when continued use of the drug with chemotherapy is utilized.

High-risk leukemia subtype becomes more common with age

High-risk leukemia subtype becomes more common with age

By

Many young adults with the most common form of acute lymphoblastic leukemia (ALL) have a high-risk subtype with a poor prognosis and could benefit from drugs used to treat other types of leukemia.

Managing adverse effects of NSCLC treatment

Managing adverse effects of NSCLC treatment

EGFR inhibitors are widely used to treat metastatic NSCLC; however, they can cause various adverse effects that differ from those caused by traditional intravenous chemotherapy.

Indications for pazopanib

Indications for pazopanib

By

Is pazopanib (Votrient) approved for the treatment of leiomyosarcoma?

Patient outcomes may be predicted by monitoring remaining leukemia after treatment

By

Using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions for acute lymphocytic leukemia patients.

Check testosterone levels of men given crizotinib for lung cancer

Testosterone levels were below the lower limit of normal in 84% of men undergoing crizotinib therapy for the treatment of lung cancer.

Leukemia arsenal has new drugs

Ponatinib (Iclusig), bosutinib (Bosulif), and omacetaxine (Synribo) are enhancing treatment for persons with certain forms of leukemia.

EGFR doesn't predict outcomes in lung cancer

EGFR mutation is not a prognostic factor in non-small cell lung cancer, but EGFR tyrosine kinase inhibitors may prolong survival after recurrence.

Ibrutinib may be a breakthrough for treatment of a rare lymphoma

Interim results confirmed the "unprecedented" single-agent activity of ibrutinib in relapsed or refractory mantle cell lymphoma.

DNA-repair problems destroy hardy leukemia cells

Leukemia stem cells that overcome drug therapy can be thwarted when deprived of RAD52, a protein key to DNA repair of these cancer cells.

Oral therapy: Managing side effects can aid adherence

Oral therapy: Managing side effects can aid adherence

Diligent patient education that addresses adherence and persistence issues can optimize outcomes in patients with gastrointestinal stromal tumors.

Annual report highlights 2012 cancer advances

The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs